Edition:
United States

Sarepta Therapeutics Inc (SRPT.OQ)

SRPT.OQ on NASDAQ Stock Exchange Global Select Market

138.45USD
15 Feb 2019
Change (% chg)

$3.57 (+2.65%)
Prev Close
$134.88
Open
$134.90
Day's High
$139.16
Day's Low
$134.00
Volume
211,412
Avg. Vol
331,960
52-wk High
$176.44
52-wk Low
$59.22

Latest Key Developments (Source: Significant Developments)

Sarepta Therapeutics Enters Into Long-Term Strategic Relationship With Aldevron For Gmp-Grade Plasmid
Wednesday, 2 Jan 2019 08:32am EST 

Jan 2 (Reuters) - Sarepta Therapeutics Inc ::SAREPTA THERAPEUTICS ENTERS INTO LONG-TERM STRATEGIC RELATIONSHIP WITH ALDEVRON FOR GMP-GRADE PLASMID IN SUPPORT OF GENE THERAPY DEVELOPMENT AND COMMERCIAL MANUFACTURING STRATEGY.SAREPTA THERAPEUTICS INC - ALDEVRON WILL PROVIDE GMP-GRADE PLASMID FOR SAREPTA'S MICRO-DYSTROPHIN DMD, LGMD PROGRAMS.  Full Article

Sarepta Therapeutics Completes Submission Of New Drug Application Seeking Approval Of Golodirsen
Thursday, 20 Dec 2018 08:30am EST 

Dec 20 (Reuters) - Sarepta Therapeutics Inc ::SAREPTA THERAPEUTICS COMPLETES SUBMISSION OF NEW DRUG APPLICATION SEEKING APPROVAL OF GOLODIRSEN (SRP-4053) IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY AMENABLE TO SKIPPING EXON 53.SAREPTA THERAPEUTICS INC - IF GOLODIRSEN NDA IS GRANTED ACCELERATED APPROVAL, ESSENCE STUDY COULD SERVE AS A POST-MARKETING CONFIRMATORY STUDY.  Full Article

Sarepta Therapeutics Announces Proposed $500 Mln Public Offering Of Common Stock
Wednesday, 7 Nov 2018 04:21pm EST 

Nov 7 (Reuters) - Sarepta Therapeutics Inc ::SAREPTA THERAPEUTICS ANNOUNCES PROPOSED $500,000,000 PUBLIC OFFERING OF COMMON STOCK.SAREPTA THERAPEUTICS - TO USE NET PROCEEDS FROM OFFERING FOR CONTINUATION, INITIATION OF FURTHER CLINICAL TRIALS, COMMERCIALIZATION, MANUFACTURING, AMONG OTHER THINGS.  Full Article

Sarepta Therapeutics Announces Plan To Submit A New Drug Application For Accelerated Approval Of Golodirsen
Monday, 12 Mar 2018 07:30am EDT 

March 12 (Reuters) - Sarepta Therapeutics Inc ::SAREPTA THERAPEUTICS ANNOUNCES PLAN TO SUBMIT A NEW DRUG APPLICATION (NDA) FOR ACCELERATED APPROVAL OF GOLODIRSEN (SRP-4053) IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) AMENABLE TO SKIPPING EXON 53.SAREPTA THERAPEUTICS INC - INTENDS TO COMPLETE A ROLLING SUBMISSION OF A GOLODIRSEN NDA BY YEAR-END 2018.SAREPTA THERAPEUTICS INC - MET WITH FDA DIVISION OF NEUROLOGY PRODUCTS IN FEBRUARY TO OBTAIN GUIDANCE ON REGULATORY PATHWAY FOR GOLODIRSEN.  Full Article

Sarepta Therapeutics Reports Q4 Non-GAAP Loss Per Share $0.28
Thursday, 1 Mar 2018 04:01pm EST 

March 1 (Reuters) - Sarepta Therapeutics Inc ::SAREPTA THERAPEUTICS ANNOUNCES FOURTH QUARTER 2017 AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS.Q4 NON-GAAP LOSS PER SHARE $0.28.Q4 GAAP LOSS PER SHARE $0.37.Q4 REVENUE $57.3 MILLION.Q4 EARNINGS PER SHARE VIEW $-0.32, REVENUE VIEW $56.5 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Sarepta Therapeutics Provides FY 2018 Rev Forecast For Exondys 51
Monday, 8 Jan 2018 01:41pm EST 

Jan 8 (Reuters) - Sarepta Therapeutics Inc ::SAREPTA THERAPEUTICS PRE-ANNOUNCES FOURTH QUARTER 2017 REVENUE AND PROVIDES FULL-YEAR 2018 REVENUE GUIDANCE FOR EXONDYS 51® (ETEPLIRSEN), REPRESENTING APPROXIMATELY 100 PERCENT YEAR-OVER-YEAR GROWTH.Q4 REVENUE $57.3 MILLION VERSUS I/B/E/S VIEW $55.8 MILLION.SEES FY 2018 REVENUE $295 MILLION TO $305 MILLION.SAYS FULL-YEAR 2018 EXONDYS 51 REVENUE GUIDANCE OF $295 - $305 MILLION.SAYS ‍FULL-YEAR 2017 EXONDYS 51 UNAUDITED REVENUE OF $154.6 MILLION​.  Full Article

Capital Ventures International Reports 5.4 Pct Passive Stake In Sarepta Therapeutics
Thursday, 21 Dec 2017 09:22am EST 

Dec 21 (Reuters) - Sarepta Therapeutics Inc ::CAPITAL VENTURES INTERNATIONAL REPORTS A 5.4 PERCENT PASSIVE STAKE IN SAREPTA THERAPEUTICS INC AS OF DECEMBER 11, 2017 - SEC FILING.  Full Article

Sarepta Therapeutics prices $475 million of convertible senior notes due 2024
Wednesday, 8 Nov 2017 07:14pm EST 

Nov 8 (Reuters) - Sarepta Therapeutics Inc :Sarepta Therapeutics prices $475 million of convertible senior notes due 2024.Sarepta Therapeutics-‍priced $475 million aggregate principal amount of convertible senior unsecured notes that will mature on November 15, 2024​.Sarepta Therapeutics - ‍notes will bear cash interest at a rate of 1.50%, payable on May 15 and November 15 of each year, beginning on May 15, 2018​.  Full Article

Sarepta Therapeutics announces proposed offering of $375 mln of convertible senior notes
Tuesday, 7 Nov 2017 04:15pm EST 

Nov 7 (Reuters) - Sarepta Therapeutics Inc :Sarepta Therapeutics announces proposed offering of $375 million of convertible senior notes due 2024.Sarepta Therapeutics Inc - ‍Chief Executive Officer indicates interest in purchasing $2 million of shares of Sarepta's common stock​.Sarepta - ‍intends to use a portion of net proceeds from offering to pay cost of certain capped call transactions​.Sarepta - ‍purchase price/share of stock bought by ingram expected to equal closing price/share of co's stock on date of pricing of offering​.  Full Article

Sarepta Therapeutics reports FDA clearance of IND for co's ppmo exon 51 candidate, srp-5051
Tuesday, 7 Nov 2017 08:30am EST 

Nov 7 (Reuters) - Sarepta Therapeutics Inc ::Sarepta Therapeutics announces FDA clearance of IND for the company's ppmo exon 51 candidate, srp-5051.Sarepta Therapeutics Inc - will immediately initiate its phase 1/2a clinical trial and begin screening patients with dmd amenable to skipping exon 51​.  Full Article